Brand preferred product step therapy requirement for Sotyktu (deucravacitinib) will now require a trial of one agent instead of three. See
Pharmacologic Treatment of Psoriasis, 5.01.629, in the
Revised pharmacy policies section.
Premera Blue Cross is an Independent Licensee of the Blue Cross Blue Shield Association
PO Box 327, Seattle, WA 98111
Discrimination is Against the Law Premera Blue Cross complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. 038503 (07-01-2021) Español|中文